AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its therapy candidates for Alzheimer’s disease, the company announced. The trial follows the release of the first positive clinical results, in which ACD856 showed a good pharmacokinetic profile (how the body affects a medicine), and was found suitable for further clinical development as an oral medication for Alzheimer’s. “It is gratifying that…
You must be logged in to read/download the full post.
The post AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden appeared first on BioNewsFeeds.